Dronabinol/Palmidrol

屈大麻酚/帕米醇

Report date: 2026/04/22 20:01:10

Base Information

Drug NameDronabinol/Palmidrol
Drug Alias Name帕米醇+屈大麻酚palmitoylethanolamide + dronabinol帕米醇/屈大麻酚Dronabinol+Palmidrol屈大麻酚+帕米醇 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid receptor agonistsPeroxisome proliferator-activated receptor α agonists
TargetsCannabinoid receptorPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsTourette SyndromeSleep Apnea, Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsYes PalmidrolDronabinol
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTherapix Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYale UniversitySciSparc Ltd
Active IndicationsN/A
Inactive IndicationsTourette SyndromeSleep Apnea, Obstructive

Other Information

ATC CodeN/A
Related LinksN/A